Cytomegalovirus, oncology immunotherapies
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
25
NCT03240731
HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease
Phase: Phase 2
Role: Collaborator
Start: Aug 10, 2017
Completion: Apr 8, 2024
Loading map...